Cosciens Biopharma (CSCI) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
13 Nov, 2026Strategic reset and acquisition
2025 actions included board reconstitution, Ceapro and corporate cost reductions, and a leadership transition focused on streamlining operations and sustainable growth.
Ceasing funding German subsidiaries in March 2026 initiated insolvency proceedings, eliminated ongoing operating-loss exposure and resulted in $10.9M of discontinued-operations income and a 4X gain in shareholders’ equity.
Shareholders approved a 1-for-150 consolidation followed by a 50-for-1 split, reducing shares by approximately two-thirds; the July 2026 Form 15 filing was intended to save ~$1.9M in annual U.S. reporting costs.
The portfolio now combines Ceapro’s oat-derived natural ingredients with Nualtis’ oral-film drug delivery, development and manufacturing capabilities.
Ceapro platform
Edmonton-based operations develop and manufacture oat-derived plant actives at a 30,000 sq. ft. GMP facility with R&D, pilot and commercial-scale capabilities.
Core ingredients include oat beta glucan, avenanthramides, superfine oat flour, oat oil and oat peptides for skin care, hair care, sensitive skin, and animal and pet applications.
Proprietary extraction, ethanol fractionation and chromatography support a documented, non-GMO portfolio; process work targets improved recovery and production efficiency across several oat ingredients.
Distribution partners provide formulation support, local regulatory expertise and access to brand owners across Europe, North America, Latin America and Asia.
9M 2026 revenue was $7.5M, up 43% YoY; gross margin was 52%, versus 33% in 2025, and annualized EBITDA run rate was ~$2.5M.
Nualtis platform and pipeline
Montreal-based Nualtis offers VersaFilm for human health and VetaFilm for veterinary use, backed by 20+ years of GMP experience and 30+ U.S. patents and patent applications.
Oral thin films address a stated $3.8B global market in 2024, forecast to reach $8.4B by 2033 at 9.3% CAGR.
Pipeline spans human and animal health, including migraine, chronic pain, opioid use disorder, erectile dysfunction, CNS disorders and OTC products; revenue streams include R&D services, manufacturing and supply, milestones and royalties.
Multiple pipeline assets are in approval-stage development or progressing toward commercialization; partners include Gensco Pharma, Xiromed, OrthoNu, Kesin Pharma and Covenant Animal Health.
Nualtis and its partners face ongoing patent litigation concerning a proposed buprenorphine product; an adverse outcome could materially delay a commercial launch.
Latest events from Cosciens Biopharma
- Nualtis adds oral-film growth potential to an established natural-ingredients platform.CSCI
Corporate presentation - Revenue rose 70% as Nualtis expanded OTF, amid losses and liquidity risks.CSCI
Q3 2026 - Q2 2026 delivered higher sales, lower expenses, and a major turnaround in profitability.CSCI
Q2 2026 - Board re-elections, auditor appointment, and share consolidation/split were all approved.CSCI
AGM 2026 - Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCI
Q1 2026 - Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCI
Q4 2025 - Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCI
Q3 2025 - Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCI
Q2 2025 - Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCI
AGM 2024